FTH Latest Press Releases

-- November 6, 2026 --

Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026 Business Wire 4:00 PM

-- November 5, 2026 --

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- November 3, 2026 --

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates Business Wire 7:30 AM

-- October 27, 2026 --

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors Business Wire 7:00 AM

-- October 23, 2026 --

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib Business Wire 9:15 AM

-- October 22, 2026 --

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- October 19, 2026 --

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026 Business Wire 7:30 AM

-- September 17, 2026 --

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors Business Wire 4:00 PM

-- September 8, 2026 --

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 Business Wire 7:30 AM

-- September 1, 2026 --

Faeth Therapeutics to Participate in Upcoming September Investor Conferences Business Wire 7:30 AM

-- August 28, 2026 --

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:30 AM

-- August 17, 2026 --

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer Business Wire 7:30 AM

-- August 14, 2026 --

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments Business Wire 7:30 AM

-- August 7, 2026 --

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:00 PM

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference Business Wire 7:30 AM

-- August 4, 2026 --

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates Business Wire 7:30 AM

-- July 23, 2026 --

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:00 PM

-- July 3, 2026 --

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:00 PM

Market Data Delayed 15 Minutes